A MaxImmun paper on the identification of human host factors required for beta-defensin-2 expression in intestinal epithelial cells upon a bacterial challenge is out in Scientific Reports. Congratulations to Weronika...
MaxImmun is a Horizon Europe project supported by the European Union, through the European Innovation Council
Grant agreement N°101129622
Start date : January 1, 2024
Duration : 48 months
An innovative therapeutic strategy to fight bacterial antibioresistance. Stay updated with the latest breakthroughs by joining our newsletter.
